This is a Validated Antibody Database (VAD) review about Chinese ha.. Ezr, based on 17 published articles (read how Labome selects the articles), using Ezr antibody in all methods. It is aimed to help Labome visitors find the most suited Ezr antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Ezr synonym: ezrin
Invitrogen
mouse monoclonal (3C12) |
| In order to assess the expression and the prognostic significance of CD133 and ezrin mRNA and protein in primary colorectal cancer cases, Invitrogen Ezr antibody (lab vision, 3c12) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 2a). IUBMB Life (2017) ncbi |
mouse monoclonal (3C12) |
| In order to explore how C-kinase potentiated protein phosphatase-1 inhibitor of 17 kDa drives Ras activity and tumorigenesis, Invitrogen Ezr antibody (NeoMarkers, 3C12) was used in western blot on human samples (fig 1b). Oncotarget (2016) ncbi |
mouse monoclonal (3C12) |
| In order to find that adenosine A2B receptors on the luminal membranes of Capan-1 cells are the functional adenosine receptors and Cl(-) channels important for anion secretion, Invitrogen Ezr antibody (Lab Vision, MS-661) was used in immunohistochemistry on rat samples at 1:400 (fig 7d). Pflugers Arch (2016) ncbi |
mouse monoclonal (3C12) |
| In order to investigate the role of transcription factors SOX4 and SOX9 during the development of bile ducts, Invitrogen Ezr antibody (Neomarkers, MS661P1) was used in immunohistochemistry - paraffin section on mouse samples at 1:200. Dev Biol (2015) ncbi |
mouse monoclonal (3C12) |
| In order to study the possible role of podoplanin and ezrin in the invasion of the ameloblastomas, Invitrogen Ezr antibody (LabVision Co., MS-661P) was used in immunohistochemistry on human samples at 1:1000. Eur J Histochem (2015) ncbi |
mouse monoclonal (3C12) |
| Invitrogen Ezr antibody (Thermo Fisher Scientific, 3C12) was used in western blot on mouse samples . Mol Cancer Res (2015) ncbi |
mouse monoclonal (3C12) |
| In order to assess the prognostic value of an immunohistochemistry-based three-protein signature model in patients with esophageal squamous cell carcinoma, Invitrogen Ezr antibody (Neomarkers, MS-661) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1). Oncotarget (2015) ncbi |
mouse monoclonal (3C12) |
| In order to explore the activity and safety of front-line dose-dense chemotherapy in high-grade soft tissue sarcoma patients and test ezrin as prognostic factor, Invitrogen Ezr antibody (NeoMarkers, 3C12) was used in immunohistochemistry - paraffin section on human samples . Sarcoma (2011) ncbi |
mouse monoclonal (3C12) |
| In order to identify intercellular adhesion molecule-1 as a new coreceptor for c-Met, Invitrogen Ezr antibody (NeoMarkers, 3C12) was used in western blot on human samples (fig 1). Mol Biol Cell (2011) ncbi |
mouse monoclonal (3C12) |
| In order to examine the raft and cytoskeletal proteins from intrauterine growth restriction and preeclampsia, Invitrogen Ezr antibody (Zymed, clone 3C12) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 3) and in western blot on human samples at 1:2000 (fig 5). J Membr Biol (2011) ncbi |
mouse monoclonal (3C12) |
| In order to explore how cell density affects the morphological and physiological properties of differentiated Caco-2 cells, Invitrogen Ezr antibody (Zymed, 3C12) was used in western blot on human samples (fig 2). J Cell Physiol (2011) ncbi |
mouse monoclonal (3C12) |
| In order to determine the origin of urinary podocalyxin, Invitrogen Ezr antibody (Zymed, 3C12) was used in immunohistochemistry on human samples (fig 7). Hum Pathol (2010) ncbi |
mouse monoclonal (3C12) |
| In order to identify a prognostic immunohistochemical signature indicative of risk of early metastasis in node-negative breast carcinomas and use this information to develop targeted therapies, Invitrogen Ezr antibody (Neomarkers, 3C12) was used in immunohistochemistry - paraffin section on human samples (tbl 1). Int J Oncol (2010) ncbi |
mouse monoclonal (3C12) |
| In order to identify prognostic immunohistochemical molecular signatures indicative of disease outcome in triple-negative breast cancers, Invitrogen Ezr antibody (Neomarkers, 3C12) was used in immunohistochemistry on human samples (tbl 3). Int J Oncol (2009) ncbi |
mouse monoclonal (3C12) |
| In order to identify prognostic signatures in breast carcinomas using quantitative immunocytochemical assays, Invitrogen Ezr antibody (Neomarkers, 3C12) was used in immunohistochemistry - paraffin section on human samples (tbl 1) and in immunohistochemistry on human samples . Int J Cancer (2009) ncbi |
mouse monoclonal (3C12) |
| In order to determine the localization and function of Duox1/Duoxa1 homologues, Invitrogen Ezr antibody (Invitrogen, 3C12) was used in immunohistochemistry - paraffin section on human samples at 1:100. FASEB J (2009) ncbi |
mouse monoclonal (3C12) |
| In order to assess the effect of granzyme M on components of the cytoskeleton, Invitrogen Ezr antibody (Zymed, 3C12) was used in western blot on human samples (fig 2). J Immunol (2008) ncbi |
Articles Reviewed
- Cao H, Zhang S, SHEN J, Wu Z, Wu J, Wang S, et al. A three-protein signature and clinical outcome in esophageal squamous cell carcinoma. Oncotarget. 2015;6:5435-48 pubmed
- Giusiano S, Secq V, Carcopino X, Carpentier S, Andrac L, Lavaut M, et al. Immunohistochemical profiling of node negative breast carcinomas allows prediction of metastatic risk. Int J Oncol. 2010;36:889-98 pubmed
- Charpin C, Giusiano S, Secq V, Carpentier S, Andrac L, Lavaut M, et al. Quantitative immunocytochemical profile to predict early outcome of disease in triple-negative breast carcinomas. Int J Oncol. 2009;34:983-93 pubmed
- Bovenschen N, de Koning P, Quadir R, Broekhuizen R, Damen J, Froelich C, et al. NK cell protease granzyme M targets alpha-tubulin and disorganizes the microtubule network. J Immunol. 2008;180:8184-91 pubmed
contribute
- If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.
questions and comments